Enhanced neurologic concept recognition using a named entity recognition model based on transformers.

Although deep learning has been applied to the recognition of diseases and drugs in electronic health records and the biomedical literature, relatively little study has been devoted to the utility of deep learning for the recognition of signs and symptoms. The recognition of signs and symptoms is critical to the success of deep phenotyping and precision medicine. We have developed a named entity recognition model that uses deep learning to identify text spans containing neurological signs and symptoms and then maps these text spans to the clinical concepts of a neuro-ontology. We compared a model based on convolutional neural networks to one based on bidirectional encoder representation from transformers. Models were evaluated for accuracy of text span identification on three text corpora: physician notes from an electronic health record, case histories from neurologic textbooks, and clinical synopses from an online database of genetic diseases. Both models performed best on the professionally-written clinical synopses and worst on the physician-written clinical notes. Both models performed better when signs and symptoms were represented as shorter text spans. Consistent with prior studies that examined the recognition of diseases and drugs, the model based on bidirectional encoder representations from transformers outperformed the model based on convolutional neural networks for recognizing signs and symptoms. Recall for signs and symptoms ranged from 59.5% to 82.0% and precision ranged from 61.7% to 80.4%. With further advances in NLP, fully automated recognition of signs and symptoms in electronic health records and the medical literature should be feasible.

Tau kinetics in Alzheimer's disease.

The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Alzheimer's disease. To better understand the causes of these elevated levels of tau, we propose a three-compartment kinetic model (brain, CSF, and plasma). The model assumes that the synthesis of tau follows zero-order kinetics (uncorrelated with compartmental tau levels) and that the release, absorption, and clearance of tau is governed by first-order kinetics (linearly related to compartmental tau levels). Tau that is synthesized in the brain compartment can be released into the interstitial fluid, catabolized, or retained in neurofibrillary tangles. Tau released into the interstitial fluid can mix with the CSF and eventually drain to the plasma compartment. However, losses of tau in the drainage pathways may be significant. The kinetic model estimates half-life of tau in each compartment (552 h in the brain, 9.9 h in the CSF, and 10 h in the plasma). The kinetic model predicts that an increase in the neuronal tau synthesis rate or a decrease in tau catabolism rate best accounts for observed increases in tau levels in the brain, CSF, and plasma found in Alzheimer's disease. Furthermore, the model predicts that increases in brain half-life of tau in Alzheimer's disease should be attributed to decreased tau catabolism and not to increased tau synthesis. Most clearance of tau in the neuron occurs through catabolism rather than release to the CSF compartment. Additional experimental data would make ascertainment of the model parameters more precise.

Heterogeneity in Blood Biomarker Trajectories After Mild TBI Revealed by Unsupervised Learning.

Concussions, also known as mild traumatic brain injury (mTBI), are a growing health challenge. Approximately four million concussions are diagnosed annually in the United States. Concussion is a heterogeneous disorder in causation, symptoms, and outcome making precision medicine approaches to this disorder important. Persistent disabling symptoms sometimes delay recovery in a difficult to predict subset of mTBI patients. Despite abundant data, clinicians need better tools to assess and predict recovery. Data-driven decision support holds promise for accurate clinical prediction tools for mTBI due to its ability to identify hidden correlations in complex datasets. We apply a Locality-Sensitive Hashing model enhanced by varied statistical methods to cluster blood biomarker level trajectories acquired over multiple time points. Additional features derived from demographics, injury context, neurocognitive assessment, and postural stability assessment are extracted using an autoencoder to augment the model. The data, obtained from FITBIR, consisted of 301 concussed subjects (athletes and cadets). Clustering identified 11 different biomarker trajectories. Two of the trajectories (rising GFAP and rising NF-L) were associated with a greater risk of loss of consciousness or post-traumatic amnesia at onset. The ability to cluster blood biomarker trajectories enhances the possibilities for precision medicine approaches to mTBI.

Schizophrenia Classification Using Resting State EEG Functional Connectivity: Source Level Outperforms Sensor Level.

Disrupted functional and structural connectivity measures have been used to distinguish schizophrenia patients from healthy controls. Classification methods based on functional connectivity derived from EEG signals are limited by the volume conduction problem. Recorded time series at scalp electrodes capture a mixture of common sources signals, resulting in spurious connections. We have transformed sensor level resting state EEG times series to source level EEG signals utilizing a source reconstruction method. Functional connectivity networks were calculated by computing phase lag values between brain regions at both the sensor and source level. Brain complex network analysis was used to extract features and the best features were selected by a feature selection method. A logistic regression classifier was used to distinguish schizophrenia patients from healthy controls at five different frequency bands. The best classifier performance was based on connectivity measures derived from the source space and the theta band.The transformation of scalp EEG signals to source signals combined with functional connectivity analysis may provide superior features for machine learning applications.

Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues.

BACKGROUND: The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neurofilament light chain, ubiquitin carboxy-terminal hydrolase-L1, tau, S100B, and glial acidic fibrillary protein. We conducted a focused literature review of unresolved issues in three areas: mode of entry into and exit from the blood, kinetics of blood biomarkers in the blood, and predictive capacity of the blood biomarkers after mTBI. FINDINGS: Although a disruption of the blood brain barrier has been demonstrated in mild and severe traumatic brain injury, biomarkers can enter the blood through pathways that do not require a breach in this barrier. A definitive accounting for the pathways that biomarkers follow from the brain to the blood after mTBI has not been performed. Although preliminary investigations of blood biomarkers kinetics after TBI are available, our current knowledge is incomplete and definitive studies are needed. Optimal sampling times for biomarkers after mTBI have not been established. Kinetic models of blood biomarkers can be informative, but more precise estimates of kinetic parameters are needed. Confounding factors for blood biomarker levels have been identified, but corrections for these factors are not routinely made. Little evidence has emerged to date to suggest that blood biomarker levels correlate with clinical measures of mTBI severity. The significance of elevated biomarker levels thirty or more days following mTBI is uncertain. Blood biomarkers have shown a modest but not definitive ability to distinguish concussed from non-concussed subjects, to detect sub-concussive hits to the head, and to predict recovery from mTBI. Blood biomarkers have performed best at distinguishing CT scan positive from CT scan negative subjects after mTBI.

A Kinetic Model for Blood Biomarker Levels After Mild Traumatic Brain Injury.

Traumatic brain injury (TBI) imposes a significant economic and social burden. The diagnosis and prognosis of mild TBI, also called concussion, is challenging. Concussions are common among contact sport athletes. After a blow to the head, it is often difficult to determine who has had a concussion, who should be withheld from play, if a concussed athlete is ready to return to the field, and which concussed athlete will develop a post-concussion syndrome. Biomarkers can be detected in the cerebrospinal fluid and blood after traumatic brain injury and their levels may have prognostic value. Despite significant investigation, questions remain as to the trajectories of blood biomarker levels over time after mild TBI. Modeling the kinetic behavior of these biomarkers could be informative. We propose a one-compartment kinetic model for S100B, UCH-L1, NF-L, GFAP, and tau biomarker levels after mild TBI based on accepted pharmacokinetic models for oral drug absorption. We approximated model parameters using previously published studies. Since parameter estimates were approximate, we did uncertainty and sensitivity analyses. Using estimated kinetic parameters for each biomarker, we applied the model to an available post-concussion biomarker dataset of UCH-L1, GFAP, tau, and NF-L biomarkers levels. We have demonstrated the feasibility of modeling blood biomarker levels after mild TBI with a one compartment kinetic model. More work is needed to better establish model parameters and to understand the implications of the model for diagnostic use of these blood biomarkers for mild TBI.

Evaluation of standard and semantically-augmented distance metrics for neurology patients.

BACKGROUND: Patient distances can be calculated based on signs and symptoms derived from an ontological hierarchy. There is controversy as to whether patient distance metrics that consider the semantic similarity between concepts can outperform standard patient distance metrics that are agnostic to concept similarity. The choice of distance metric can dominate the performance of classification or clustering algorithms. Our objective was to determine if semantically augmented distance metrics would outperform standard metrics on machine learning tasks. METHODS: We converted the neurological findings from 382 published neurology cases into sets of concepts with corresponding machine-readable codes. We calculated patient distances by four different metrics (cosine distance, a semantically augmented cosine distance, Jaccard distance, and a semantically augmented bipartite distance). Semantic augmentation for two of the metrics depended on concept similarities from a hierarchical neuro-ontology. For machine learning algorithms, we used the patient diagnosis as the ground truth label and patient findings as machine learning features. We assessed classification accuracy for four classifiers and cluster quality for two clustering algorithms for each of the distance metrics. RESULTS: Inter-patient distances were smaller when the distance metric was semantically augmented. Classification accuracy and cluster quality were not significantly different by distance metric. CONCLUSION: Although semantic augmentation reduced inter-patient distances, we did not find improved classification accuracy or improved cluster quality with semantically augmented patient distance metrics when applied to a dataset of neurology patients. Further work is needed to assess the utility of semantically augmented patient distances.

Synthesis of novel compounds containing morpholine and 5(4H)-oxazolone rings as potent tyrosinase inhibitors.

In this study, six new compounds containing morpholine and 5(4H)-oxazolone rings were synthesized. Structures of the new compounds using IR, (1)H NMR, mass spectroscopy and elemental analysis were characterized. All new compounds (4a-4f) have a strong inhibitory effect against mushroom tyrosinase. And the inhibitory effects of these compounds were compared with Kojic acid as standard.